Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
PERF
Perfect Corp.
HD skin diagnostics deployed in aesthetic clinics, representing healthcare-oriented diagnostic software.
|
$176.20M |
$1.71
+0.59%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$175.07M |
$1.88
+0.53%
|
|
PRE
Prenetics Global Limited
Insighta's FRAGMA liquid biopsy enables multi-cancer early detection.
|
$174.53M |
$14.26
-6.89%
|
|
OSUR
OraSure Technologies, Inc.
OraSure's core offerings include diagnostic equipment such as OraQuick rapid tests and molecular diagnostics platforms.
|
$174.07M |
$2.37
-3.27%
|
|
IMDX
Insight Molecular Diagnostics Inc.
IMDX directly provides Laboratory Testing & Advisory Services via its GraftAssure family (LDTs/kits) for transplant rejection monitoring.
|
$172.86M |
$6.14
-0.16%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$171.69M |
$1.11
+1.83%
|
|
XGN
Exagen Inc.
Exagen provides diagnostic testing services and operates lab facilities for autoimmune diagnostics.
|
$170.31M |
$7.73
+0.39%
|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$165.61M |
$2.25
+2.51%
|
|
NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
Directly produces oncology-focused biotech therapies; lead programs NEO100/NEO212 targeting brain cancers.
|
$164.29M |
$8.71
-1.47%
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$163.76M |
$3.40
+11.68%
|
|
NYXH
Nyxoah S.A.
Genio is a neuromodulation implant system (implantable medical device) for obstructive sleep apnea.
|
$160.60M |
$4.60
+0.66%
|
|
PROF
Profound Medical Corp.
Profound's flagship TULSA-PRO is a surgical device used for MR-guided prostate tissue ablation.
|
$159.32M |
$6.50
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$157.69M |
$2.87
+3.24%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$157.07M |
$1.75
+3.87%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
CRDF
Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company focused on oncology therapeutics, with its lead asset targeting cancer (onvansertib).
|
$155.67M |
$2.33
+10.66%
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$154.27M |
$6.07
-0.41%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$153.73M |
$1.46
+1.04%
|
|
IPHA
Innate Pharma S.A.
Innate Pharma focuses on oncology therapies, including antibody-based approaches, making Biotech - Oncology a core business area.
|
$153.03M |
$1.88
+1.08%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$152.95M |
$2.22
-1.33%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$152.26M |
$1.31
+2.34%
|
|
RELL
Richardson Electronics, Ltd.
Medical devices and equipment manufacturing including CT X-ray tubes and related products remain part of the portfolio.
|
$152.17M |
$10.53
+3.09%
|
|
APYX
Apyx Medical Corporation
APYX designs and sells medical devices (Renuvion helium plasma platform and AYON body contouring system) used in surgical procedures.
|
$151.66M |
$4.03
+0.75%
|
|
AVR
Anteris Technologies Global Corp.
Company directly develops and sells medical devices for the cardiovascular field, specifically the DurAVR transcatheter heart valve and related biomaterial technologies.
|
$150.38M |
$4.17
+8.31%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$149.66M |
$9.15
+2.23%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$149.46M |
$4.64
+7.52%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$147.69M |
$16.93
+0.03%
|
|
PLX
Protalix BioTherapeutics, Inc.
Protalix manufactures recombinant proteins/enzymes (e.g., Elelyso, Elfabrio) using its plant-based ProCellEx system.
|
$145.91M |
$1.83
+2.51%
|
|
RCMT
RCM Technologies, Inc.
RCMT's offerings align with Healthcare Services & Facilities through its healthcare staffing/model and service delivery to care institutions.
|
$145.84M |
$19.55
-2.40%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$145.59M |
$11.90
+4.71%
|
|
AGEN
Agenus Inc.
Agenus highlights antibody discovery platforms and proprietary display technologies enabling BOT/BAL development.
|
$144.98M |
$4.57
+4.34%
|
Showing page 23 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
